Dilsher Dhoot, MD
Retina Specialist · Santa Barbara, CANPI 1508070566
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,332,497 of the $1,931,839 with a category attached, or 69.0%. 35 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 37.3% of the total. Among retina specialist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,744 payments — averaging $1107.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$720K
- Apellis Pharmaceuticals, Inc.$323K
- Genentech USA, Inc.$190K
- Ocular Therapeutix, Inc.$159K
- Alimera Sciences, Inc.$114K
- Novartis$111K
- plus $316K from 29 others
Across 943 payments — averaging $6829.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2.1M
- Ocular Therapeutix, Inc.$1.4M
- Novartis$1.4M
- Regeneron$815K
- Apellis Pharmaceuticals, Inc.$416K
- Boehringer Ingelheim$75K
- plus $239K from 7 others
What the payments were for
- Consulting fees$350,61618%
- Speaking & faculty fees$1,332,49769%
- Travel & lodging$199,78010%
- Food & beverage$46,3842%
- Education$80%
- Gifts$2,2990%
- Ownership interest$2550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$458,378
- EYLEA HD$268,522
- Syfovre$246,087
- Cimerli$127,199
- VABYSMO$113,166
- Iluvien$112,970
- YUTIQ$80,569
- Lucentis$72,377
- BEOVU$56,444
- PURIFIED CORTROPHIN GEL$15,733
- Non-Covered Product$14,538
- STELLARIS ELITE$11,393
- STELLARIS$8,277
- SUSVIMO$5,515
- OZURDEX$5,247
- EYP-1901$4,747
- XIPERE$4,454
- PANORAMIC OPHTHALMOSCOPE$4,000
- Izervay$3,852
- VISULAS 532s$2,129
How this compares
$1,931,839 in reported general payments places this provider in the 95th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 343 | $15,035 |
| Atropine Sulfate | 143 | $6,709 |
| LumiganBimatoprost | 13 | $5,421 |
| Ketorolac Tromethamine | 171 | $5,152 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $4,120 |
| Brimonidine Tartrate | 137 | $4,023 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 249 | $3,465 |
| Loteprednol Etabonate | 15 | $3,410 |
| Travoprost | 17 | $1,944 |
| ErythromycinErythromycin Base | 165 | $1,725 |
| Difluprednate | 14 | $1,555 |
| Ciprofloxacin Hcl | 101 | $1,536 |
| Fluorometholone | 16 | $1,478 |
| Latanoprost | 117 | $653 |
| MoxifloxacinMoxifloxacin Hcl | 21 | $538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $7,886 | $5,42113 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $15 | $3,41015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 187 retina specialist providers in California.
Other retina specialist in Santa Barbara
- Nathan SteinleSanta Barbara$1.1M
- Dante PieramiciSanta Barbara$267K
- Robert AverySanta Barbara$180K
- Nika BagheriSanta Barbara$73K
- Daniel LearnedSanta Barbara$49K
- Stephen CouvillionSanta Barbara$43K
- Alessandro CastellarinSanta Barbara$24K
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Roger GoldbergWalnut Creek$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.